Bullish for Small/Midcaps: CDMO Pharma, Capital Goods Offer Growth

Ashish Chaturmohta of JM Financial has pointed out that despite the Nifty being stuck in a range, significant wealth creation is occurring in the small and midcap segments of the Indian market. He specifically highlighted CDMO pharma, capital markets, and capital goods as sectors with strong earnings momentum and structural demand, making them attractive investment themes.

This analysis is crucial for traders as it redirects attention from the often-discussed large-cap indices to specific pockets of the market showing robust growth. In a sideways market, identifying such high-potential sectors and market caps can be key to generating alpha, suggesting a tactical shift in investment strategy for the coming months.

While no specific stocks are named, the commentary is broadly positive for companies operating in the CDMO (Contract Development and Manufacturing Organization) pharma space, capital market intermediaries (brokers, asset managers), and capital goods manufacturers. Investors might see increased interest and inflows into small and midcap stocks within these sectors, potentially leading to price appreciation. The broader Nifty may remain subdued, but these segments could show independent strength.

Traders should monitor the performance of small and midcap indices relative to the Nifty for confirmation of this trend. Look for specific companies in the mentioned sectors that are reporting strong earnings and have clear growth catalysts. Keep an eye on FII/DII flows into these segments and any policy announcements that could further boost capital goods or pharma sectors.

• •Nifty is stuck in a range.
• •Small and midcaps are where real money is being made.
• •Ashish Chaturmohta of JM Financial identified CDMO pharma, capital markets, and capital goods as promising sectors.
• •These sectors show strong earnings momentum and structural demand.
• •Risk flag: Potential for increased volatility in small and midcaps compared to large caps.